Skip to main content
Contact Us
Subscribe
E-Edition
71°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AstraZeneca
< Previous
1
2
3
4
5
6
7
Next >
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
May 21, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
May 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
May 02, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
May 01, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
April 29, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Q1 2024 results
April 25, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
April 16, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
April 11, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
April 05, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
April 05, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
April 02, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
March 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
March 18, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
March 13, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
February 23, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
February 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
February 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
February 16, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Full year and Q4 2023 Financial Results
February 08, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
February 06, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors
January 29, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
January 22, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
January 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
December 26, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
GRCL
WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
December 21, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
December 12, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca advances scientific leadership in hematology at ASH 2023
November 29, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
November 20, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
November 17, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
November 09, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.